Data from clinical study of Pharmalink's Nefecon® to be presented at American Society of Nephrology's Kidney Week 2014

Pharmalink extends patent protection for Nefecon® treatment for renal disease

Pharmalink elects Bengt Julander as Chairman

Pharmalink's core patents for Nefecon® treatment for renal disease granted in United States, Europe, China and Hong Kong

Pharmalink strengthens its Board of Directors

Pharmalink completes enrolment of patients into Phase IIB clinical study (NEFIGAN) of Nefecon®